[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_iT2Y3GaslI95w8iWepGsyRPPpnYg7fULhwTx451XjM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":38,"rows":45},"Medtronic Vascular",[4],60,false,10,1,53928,0,58,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Coronary Artery Disease",34,{"name":18,"count":19},"Cardiovascular Diseases",19,{"name":21,"count":22},"Hypertension",14,{"name":24,"count":8},"Vascular Diseases",{"name":26,"count":27},"Ischemic Heart Disease",9,{"name":29,"count":30},"Arteriosclerosis",8,{"name":32,"count":33},"Stenotic Coronary Lesion",5,{"name":35,"count":36},"Myocardial Ischemia",4,[],[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,71],{"intervention":47,"totalTrials":9,"cells":48},"Thienopyridine Therapy",{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":69},{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[],{"trials":58,"activeCount":11},[59],{"nctId":60,"briefTitle":61,"status":62,"phases":63,"primaryCompletion":64,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":68},"NCT01069003","EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events","COMPLETED",[43],"2014-04","2010-04",2272,[15],[47],{"trials":70,"activeCount":11},[],{"intervention":72,"totalTrials":9,"cells":73},"Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT",{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":84},{"trials":75,"activeCount":11},[],{"trials":77,"activeCount":11},[],{"trials":79,"activeCount":11},[],{"trials":81,"activeCount":11},[],{"trials":83,"activeCount":11},[],{"trials":85,"activeCount":11},[86],{"nctId":87,"briefTitle":88,"status":62,"phases":89,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":95},"NCT03647475","A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)",[44],"2020-03-10","2021-04-22","2018-10-01",752,[15],[72]]